Grunt Thomas (31 results)
Published by Paleontological Society 2004
- Softcover
Seller: Katsumi-san Co., Cambridge, MA, U.S.A.Katsumi-san Co.
Contact seller5-star sellerCondition: Used - Very good
US$ 11.95
US$ 3.95 shippingShips within U.S.A.Quantity: 1 available
Soft cover. Condition: Very Good. Volume has minor wear; tight, text clean. Paginated 827-1029 , illustrated. Oversize [br 6].
Language: English
Published by Springer 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: BuchZeichen-Versandhandel, Freiburg, , GermanyBuchZeichen-Versandhandel
Contact seller5-star sellerCondition: Used - Fine
US$ 52.95
US$ 11.40 shippingShips from Germany to U.S.A.Quantity: 1 available
Condition: Gebraucht - Sehr gut. SPRINGER VERLAG - 2011 - H4.
Language: English
Published by Birkhäuser 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: Buchpark, Trebbin, , GermanyBuchpark
Contact seller5-star sellerCondition: Used - Fine
US$ 61.29
US$ 120.31 shippingShips from Germany to U.S.A.Quantity: 1 available
Condition: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant…tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: Ria Christie Collections, Uxbridge, United KingdomRia Christie Collections
Contact seller5-star sellerCondition: New
US$ 185.44
US$ 15.82 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
Condition: New. In.
Language: English
Published by Springer 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: Ria Christie Collections, Uxbridge, United KingdomRia Christie Collections
Contact seller5-star sellerCondition: New
US$ 187.43
US$ 15.82 shippingShips from United Kingdom to U.S.A.Quantity: Over 20 available
Condition: New. In.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: New
US$ 200.10
US$ 2.64 shippingShips within U.S.A.Quantity: 15 available
Condition: New.
Language: English
Published by Springer 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: New
US$ 202.11
US$ 2.64 shippingShips within U.S.A.Quantity: 15 available
Condition: New.
Language: English
Published by Springer 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: Used - As new
US$ 209.04
US$ 2.64 shippingShips within U.S.A.Quantity: 15 available
Condition: As New. Unread book in perfect condition.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: Books Puddle, New York, NY, U.S.A.Books Puddle
Contact seller4-star sellerCondition: New
US$ 228.45
US$ 3.99 shippingShips within U.S.A.Quantity: 4 available
Condition: New. pp. 122.
Language: English
Published by Birkhauser Verlag AG 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrelandKennys Bookshop and Art Galleries Ltd.
Contact seller5-star sellerCondition: New
US$ 231.15
US$ 12.03 shippingShips from Ireland to U.S.A.Quantity: 15 available
Condition: New. Growth factor receptors have long been known to drive malignant transformation and cancer progression. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease.…Thsi book deals with this topic. Editor(s): Zielinski, Christoph C.; Sibilia, Maria; Bergen, Elisabeth; Grunt, Thomas W.; Bartsch, Rupert. Series: Milestones in Drug Therapy. Num Pages: 120 pages, biography. BIC Classification: MJCL; MJCM; MMG. Category: (P) Professional & Vocational. Dimension: 244 x 164 x 14. Weight in Grams: 384. . 2011. Hardback. . . . .
Language: English
Published by Springer 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: Books Puddle, New York, NY, U.S.A.Books Puddle
Contact seller4-star sellerCondition: New
US$ 236.11
US$ 3.99 shippingShips within U.S.A.Quantity: 4 available
Condition: New. pp. 122.
More imagesLanguage: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: preigu, Osnabrück, Germanypreigu
Contact seller5-star sellerCondition: New
US$ 165.23
US$ 80.21 shippingShips from Germany to U.S.A.Quantity: 5 available
Taschenbuch. Condition: Neu. Drugs for HER-2-positive Breast Cancer | Maria Sibilia (u. a.) | Taschenbuch | Milestones in Drug Therapy | x | Englisch | 2013 | Springer | EAN 9783034803182 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anb…ieter: preigu.
Language: English
Published by Springer Basel, Birkhäuser 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
US$ 189.40
US$ 70.90 shippingShips from Germany to U.S.A.Quantity: 1 available
Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors.… With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
US$ 197.25
US$ 69.87 shippingShips from Germany to U.S.A.Quantity: 1 available
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant…tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: Revaluation Books, Exeter, , United KingdomRevaluation Books
Contact seller5-star sellerCondition: New
US$ 263.42
US$ 13.20 shippingShips from United Kingdom to U.S.A.Quantity: 2 available
Paperback. Condition: Brand New. 2011 edition. 119 pages. 9.25x6.10x0.28 inches. In Stock.
Language: English
Published by Birkhauser 2010
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: Revaluation Books, Exeter, , United KingdomRevaluation Books
Contact seller5-star sellerCondition: New
US$ 264.98
US$ 13.20 shippingShips from United Kingdom to U.S.A.Quantity: 2 available
Hardcover. Condition: Brand New. 1st edition. 110 pages. 9.25x6.50x0.50 inches. In Stock.
Language: English
Published by Birkhauser Verlag AG 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
Seller: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore
Contact seller5-star sellerCondition: New
US$ 275.59
US$ 10.50 shippingShips within U.S.A.Quantity: 15 available
Condition: New. Growth factor receptors have long been known to drive malignant transformation and cancer progression. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease.…Thsi book deals with this topic. Editor(s): Zielinski, Christoph C.; Sibilia, Maria; Bergen, Elisabeth; Grunt, Thomas W.; Bartsch, Rupert. Series: Milestones in Drug Therapy. Num Pages: 120 pages, biography. BIC Classification: MJCL; MJCM; MMG. Category: (P) Professional & Vocational. Dimension: 244 x 164 x 14. Weight in Grams: 384. . 2011. Hardback. . . . . Books ship from the US and Ireland.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: Mispah books, Redhill, SURRE, United KingdomMispah books
Contact seller4-star sellerCondition: Used - As new
US$ 297.78
US$ 33.00 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
Paperback. Condition: Like New. Like New. book.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contact seller5-star sellerCondition: Used - As new
US$ 328.13
US$ 2.64 shippingShips within U.S.A.Quantity: 15 available
Condition: As New. Unread book in perfect condition.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
- Print on Demand
Seller: Brook Bookstore On Demand, Napoli, NA, ItalyBrook Bookstore On Demand
Contact seller3-star sellerCondition: New
US$ 149.01
US$ 4.58 shippingShips from Italy to U.S.A.Quantity: Over 20 available
Condition: new. Questo è un articolo print on demand.
Language: English
Published by Springer 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
- Print on Demand
Seller: Brook Bookstore On Demand, Napoli, NA, ItalyBrook Bookstore On Demand
Contact seller3-star sellerCondition: New
US$ 149.01
US$ 6.30 shippingShips from Italy to U.S.A.Quantity: Over 20 available
Condition: new. Questo è un articolo print on demand.
Language: English
Published by Springer Basel, Springer Basel Jan 2011 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
- Print on Demand
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, , GermanyBuchWeltWeit Ludwig Meier e.K.
Contact seller5-star sellerCondition: New
US$ 189.40
US$ 26.35 shippingShips from Germany to U.S.A.Quantity: 2 available
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in m…alignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting. 120 pp. Englisch.
Language: English
Published by Springer Basel Feb 2013 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
- Print on Demand
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, , GermanyBuchWeltWeit Ludwig Meier e.K.
Contact seller5-star sellerCondition: New
US$ 189.40
US$ 26.35 shippingShips from Germany to U.S.A.Quantity: 2 available
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase fami…ly in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting. 120 pp. Englisch.
Language: English
Published by Springer Basel 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
- Print on Demand
Seller: moluna, Greven, , Germanymoluna
Contact seller5-star sellerCondition: New
US$ 160.69
US$ 56.13 shippingShips from Germany to U.S.A.Quantity: Over 20 available
Kartoniert / Broschiert. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Contemporary monograph on the treatment of breast cancer.-Gives a comprehensive account of drugs for HER2-positive breast cancer.-A valuable source of information for researchers and clinician…s from the fields of oncology and pharmacology.
Language: English
Published by Springer Basel 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
- Print on Demand
Seller: moluna, Greven, , Germanymoluna
Contact seller5-star sellerCondition: New
US$ 160.69
US$ 56.13 shippingShips from Germany to U.S.A.Quantity: Over 20 available
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Contemporary monograph on the treatment of breast cancer.-Gives a comprehensive account of drugs for HER2-positive breast cancer.-A valuable source of information for researchers and clinicians from the fields of onco…logy and pharmacology.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
- Print on Demand
Seller: Majestic Books, Hounslow, , United KingdomMajestic Books
Contact seller4-star sellerCondition: New
US$ 240.85
US$ 8.58 shippingShips from United Kingdom to U.S.A.Quantity: 4 available
Condition: New. Print on Demand pp. 122.
Language: English
Published by Springer Basel, Birkhäuser Jan 2011 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
- Print on Demand
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000
Contact seller5-star sellerCondition: New
US$ 189.40
US$ 68.75 shippingShips from Germany to U.S.A.Quantity: 1 available
Buch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malig…nant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.Springer Nature c/o IBS, Benzstrasse 21, 48619 Heek 120 pp. Englisch.
Language: English
Published by Springer Basel, Springer Basel Feb 2013 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
- Print on Demand
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000
Contact seller5-star sellerCondition: New
US$ 189.40
US$ 68.75 shippingShips from Germany to U.S.A.Quantity: 1 available
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family i…n malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 120 pp. Englisch.
Language: English
Published by Springer 2011
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Hardcover
- Print on Demand
Seller: Majestic Books, Hounslow, , United KingdomMajestic Books
Contact seller4-star sellerCondition: New
US$ 248.61
US$ 8.58 shippingShips from United Kingdom to U.S.A.Quantity: 4 available
Condition: New. Print on Demand pp. 122.
Language: English
Published by Springer 2013
Series: Milestones in Drug Therapy, Book 3 of 16. Book 3 of 16 - Milestones in Drug Therapy
- Softcover
- Print on Demand
Seller: Biblios, frankfurt am main, HESSE, GermanyBiblios
Contact seller4-star sellerCondition: New
US$ 256.35
US$ 11.40 shippingShips from Germany to U.S.A.Quantity: 4 available
Condition: New. PRINT ON DEMAND pp. 122.
